Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

A Change in the Trend of Quality Reporting in Leprosy Trials: A Systematic Review

Author(s): Pugazhenthan Thangaraju*, Pranav Gaurangbhai Sheth, Hemasri Velmurugan, Sajitha Venkatesan and Aravind Kumar Balan

Volume 23, Issue 4, 2023

Published on: 21 March, 2023

Article ID: e240223214010 Pages: 8

DOI: 10.2174/1871526523666230224104113

Price: $65

Abstract

Background: Leprosy is a communicable disease caused by bacteria Mycobacterium leprae. Despite all attempts, it has not been eradicated in several underdeveloped nations since the start of the antibiotic age. It's a social issue as well as a stigmatised disease. Due to these restrictions, randomised controlled trials in leprosy confront numerous obstacles, which are reflected in the quality of study reporting.

Objectives: The objective of this study is to use the Consolidated Standard for Reporting Trials (CONSORT) 2010 checklist to assess the quality of leprosy trial reporting.

Methods: We assess the quality of reporting of randomised control trials on leprosy conducted after 2010 in the PubMed database, using the CONSORT checklist 2010. Second, we compare the quality of RCT reporting before and after the release of the CONSORT guidelines in 2010.

Results: A total of 19 full-text eligible articles were examined and included in the final list of articles, which were then evaluated further. 4 out of 19 trials had a compliance percentage of more than 75%. 6 out of 19 trials had compliance percentage of 50% to 75%. 9 trials had a compliance percentage of below 50%. Highest compliance was 86.48% and the lowest compliance was 32.43%. When compared with trials before 2010, we could see an improvement in some criteria showing a statistically significant rise in comparison with trials conducted before 2010.

Conclusion: Leprosy is still a concern in developing countries, which have failed to eradicate the disease despite their best efforts and resources. The compliance of leprosy related RCTs has improved since the introduction of the CONSORT guidelines, but the quality of reporting still remains on the lower side.

Graphical Abstract

[1]
WHO Leprosy. 2021. Available from: https://www.who.int/health-topics/leprosy#tab=tab_1
[2]
National Health Portal. 2021. Available from: https://www.nhp.gov.in/disease/skin/leprosy
[3]
Global leprosy (hansen disease) update, 2020: Impact of COVID-19 on the global leprosy control. Weekly epidemiological record 2021; 9 September; 96: 421-44..
[4]
Grossman J, Mackenzie FJ. The randomized controlled trial: Gold standard, or merely standard? Perspect Biol Med 2005; 48(4): 516-34.
[http://dx.doi.org/10.1353/pbm.2005.0092] [PMID: 16227664]
[5]
Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. BMC Med 2010; 8(7): 604-12.
[http://dx.doi.org/10.1186/1741-7015-8-18]
[6]
Richardus RA, van der Zwet K, van Hooij A, et al. Longitudinal assessment of anti-PGL-I serology in contacts of leprosy patients in Bangladesh. PLoS Negl Trop Dis 2017; Dec 11 11(12): e0006083.
[http://dx.doi.org/10.1371/journal.pntd.0006083]
[7]
Richardus R, Alam K, Kundu K, et al. Effectiveness of single-dose rifampicin after BCG vaccination to prevent leprosy in close contacts of patients with newly diagnosed leprosy: A cluster randomized controlled trial. Int J Infect Dis 2019; 88: 65-72.
[http://dx.doi.org/10.1016/j.ijid.2019.08.035] [PMID: 31499206]
[8]
Cruz RCDS, Buhrer-Sekula S, Penna GO, et al. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Adverse effects approach. An Bras Dermatol 2018; 93(3): 377-84.
[9]
Lockwood DN, Darlong J, Govindharaj P. AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and Type 1 reactions in India: Main findings. PLoS Negl Trop Dis 2017; 11(3): e0005348.
[http://dx.doi.org/10.1371/journal.pntd.0005348]
[10]
Penna GO, Buhrer-Sekula S, Kerr LRS. Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients. PLoS Negl Trop Dis 2017; 11(7): e0005725.
[http://dx.doi.org/10.1371/journal.pntd.0005725]
[11]
Hungria EM, Oliveira RM, Penna GO, et al. Can baseline ML Flow test results predict leprosy reactions? An investigation in a cohort of patients enrolled in the uniform multidrug therapy clinical trial for leprosy patients in Brazil. Infect Dis Poverty 2016; 5(1): 110.
[http://dx.doi.org/10.1186/s40249-016-0203-0]
[12]
Dadun D, Peters RMH, van Brakel WH. Assessing the impact of the twin track socio-economic intervention on reducing leprosy-related stigma in cirebon district, Indonesia. Int J Environ Res Public Health 2019; 16(3): 349.
[http://dx.doi.org/10.3390/ijerph16030349]
[13]
Wagenaar I, Post E, Brandsma W. Effectiveness of 32 versus 20 weeks of prednisolone in leprosy patients with recent nerve function impairment: A randomized controlled trial. PLoS Negl Trop Dis 2017; 11(10): e0005952.
[http://dx.doi.org/10.1371/journal.pntd.0005952]
[14]
Peters RM. A cluster-randomized controlled intervention study to assess the effect of a contact intervention in reducing leprosy-related stigma in Indonesia. PLoS Negl Trop Dis 2015; 9(10): e0004003.
[http://dx.doi.org/10.1371/journal.pntd.0004003]
[15]
Rivoire BL, Groathouse NA, TerLouw S. Safety and efficacy assessment of two new leprosy skin test antigens: Randomized double blind clinical study. PLoS Negl Trop Dis 2014; 8(5): e2811.
[http://dx.doi.org/10.1371/journal.pntd.0002811]
[16]
Lambert SM, Alembo DT, Nigusse SD, et al. A randomized controlled double blind trial of ciclosporin versus prednisolone in the management of leprosy patients with new type 1 reaction, in Ethiopia. PLoS Negl Trop Dis 2016; 10(4): e0004502.
[http://dx.doi.org/10.1371/journal.pntd.0004502]
[17]
Idema WJ, Majer IM, Pahan D. Cost-effectiveness of a chemoprophylactic intervention with single dose rifampicin in contacts of new leprosy patients. PLoS Negl Trop Dis 2010; 4(11): e874.
[http://dx.doi.org/10.1371/journal.pntd.0000874]
[18]
Richardus RA, Alam K, Pahan D, Feenstra SG, Geluk A, Richardus JH. The combined effect of chemoprophylaxis with single dose rifampicin and immunoprophylaxis with BCG to prevent leprosy in contacts of newly diagnosed leprosy cases: A cluster randomized controlled trial (MALTALEP study). BMC Infect Dis 2013; 13: 456.
[http://dx.doi.org/10.1186/1471-2334-13-456]
[19]
Kumar A, Girdhar A, Girdhar B. A randomized controlled trial to compare cure and relapse rate of paucibacillary multidrug therapy with monthly rifampicin, ofloxacin, and minocycline among paucibacillary leprosy patients in Agra District, India. Indian J Dermatol Venereol Leprol 2015; 81(4): 356-62.
[http://dx.doi.org/10.4103/0378-6323.159929] [PMID: 26144850]
[20]
Penna GO, Pontes MAA, Cruz R, Gonçalves HS, Penna MLF, Bührer-Sékula S. A clinical trial for uniform multidrug therapy for leprosy patients in Brazil: rationale and design. Mem Inst Oswaldo Cruz 2012; 107 (Suppl. 1): 22-7.
[http://dx.doi.org/10.1590/S0074-02762012000900005] [PMID: 23283449]
[21]
Gonçalves HS, Pontes MAA, Bührer-Sékula S, et al. Brazilian clinical trial of uniform multidrug therapy for leprosy patients: the correlation between clinical disease types and adverse effects. Mem Inst Oswaldo Cruz 2012; 107 (Suppl. 1): 74-8.
[http://dx.doi.org/10.1590/S0074-02762012000900013] [PMID: 23283457]
[22]
Lambert SM, Nigusse SD, Alembo DT, et al. Comparison of efficacy and safety of ciclosporin to prednisolone in the treatment of erythema nodosum leprosum: Two randomised, double blind, controlled pilot studies in Ethiopia. PLoS Negl Trop Dis 2016; 10(2): e0004149.
[http://dx.doi.org/10.1371/journal.pntd.0004149]
[23]
Véras LST, Vale RGS, Mello DB, et al. Electromyography function, disability degree, and pain in leprosy patients undergoing neural mobilization treatment. Rev Soc Bras Med Trop 2012; 45(1): 83-8.
[http://dx.doi.org/10.1590/S0037-86822012000100016] [PMID: 22370834]
[24]
Walker SL, Nicholls PG, Dhakal S. A phase two randomised controlled double blind trial of high dose intravenous methylprednisolone and oral prednisolone versus intravenous normal saline and oral prednisolone in individuals with leprosy type 1 reactions and/or nerve function impairment. PLoS Negl Trop Dis 2011; 5(4): e1041.
[http://dx.doi.org/10.1371/journal.pntd.0001041]
[25]
Forsetlund L, Reinar LM. Quality of reporting and of methodology of studies on interventions for trophic ulcers in leprosy: A systematic review. Indian J Dermatol Venereol Leprol 2008; 74(4): 331-7.
[http://dx.doi.org/10.4103/0378-6323.42895] [PMID: 18797052]
[26]
Altman DG. Better reporting of randomised controlled trials: The CONSORT statement. BMJ 1996; 313(7057): 570-1.
[http://dx.doi.org/10.1136/bmj.313.7057.570] [PMID: 8806240]
[27]
Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c869.
[http://dx.doi.org/10.1136/bmj.c869]
[28]
Walton RT, Fritschi EP, Umapathy VA. Treatment of plantar ulcers in leprosy patients in the community with adhesive zinc tape. Lepr Rev 1986; 57(1): 53-6.
[http://dx.doi.org/10.5935/0305-7518.19860009] [PMID: 3517537]
[29]
Merkow RP, Kaji AH, Itani KMF. The CONSORT framework. JAMA Surg 2021; 156(9): 877-8.
[http://dx.doi.org/10.1001/jamasurg.2021.0549] [PMID: 33825818]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy